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Abstract 
 
Rheumatoid Arthritis (RA) is the most common autoimmune disease related to the joints 
and one of the most severe. Despite the intensive investigation, RA inflammatory process 
remains unknown and finding effective and long lasting therapies that specifically target RA is 
a challenging task. In RA the pro-inflammatory macrophages persist in the inflammation site 
and frequently overexpress cytokines and other biomolecule factors that amplify even more 
the inflammatory process. However, during RA, the macrophages also overexpress the CD64 
surface marker that drives the search for new specific RA therapies. 
This work proposed an innovative approach for RA therapy, taking advantage of the new 
emerging field of nanomedicine and the tools that it offers for targeted therapies. This study 
aimed to develop a targeted theranostic system for intravenous administration, using Solid Lipid 
Nanoparticles (SLN), a biocompatible and biodegradable colloidal delivery system, widely 
researched for medical applications, to function as a drug delivery system. The SLNs were 
encapsulated with methotrexate (MTX) and superparamagnetic iron oxide nanoparticles 
(SPIONs), to be used as therapeutic and imaging agents, respectively. The SLNs were also 
surface-functionalized with an anti-CD64 antibody that specifically targets RA-infected 
macrophages. 
A total of eight different cetyl palmitate and stearic acid SLN formulations were produced 
using in an organic solvent-free emulsification-sonication method that combined high shear 
homogenization and ultra-sonication in order to compare the influence of each component 
present (MTX, SPIONs and anti-CD64) on NP characteristics. Particle size was assess by dynamic 
light scattering and analyzed by transmission electron microscopy and surface charge (zeta 
potential) mas measured by phase analysis light scattering. The placebo formulations showed 
sizes around 160 nm and zeta potentials of – 40 mV. Results also showed that MTX did not 
influence significantly NP properties, whereas SPIONs encapsulation caused an increase in both 
size and zeta values. The antibody conjugation caused an increased in zeta potential as 
expected but an unexpected decrease in NP size was observed. However, all the formulations 
presented sizes below 200 nm and zeta values lower than -12 mV, indicating suitable 
characteristics as nanosystems for intravenous administration. The stability of these 
formulations was also proven up to one month for the non-conjugated formulations. 
Nanoparticle morphology was analyzed by transmission electron microscopy (TEM). 
TEM photographs indicated that the SPIONs were encapsulated inside the SLN matrix. Also, 
it was possible to observe small deformity and aggregation of NPs, while formulations without 
SPIONs presented a spherical shape with little aggregation. FT-IR was used to confirm the 
presence of MTX in the SLNs as well as the successful conjugation of the antibody to the SLN. 
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MTX association efficiency was determined by UV/Vis spectrophotometry, rendering values non-
lower than 98% for both MTX-loaded SLNs and MTX- and SPIONs-loaded SLNs. 
In vitro studies were performed with THP-1 cells and enabled to assess the cytotoxicity of 
the developed formulations. MTT and LDH assays demonstrated that the formulations were 
biocompatible and presented low cytotoxicity a concentrations lower than 500 µg/mL, but 
there were no significant changes when comparing the different formulations at the same 
concentrations unexpectedly. 
This study could provide an effective and viable approach for future theranostic strategies. 
It was proven that the proposed NP were not cytotoxic, that both a therapeutic and imaging 
agent could be co-encapsulated and the SLN functionalized for a potential future application 
such as anti-body specific targeting.. The proposed formulations are, therefore, promising 
candidates for future theranostic applications. 
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“A single dream is more powerful than a thousand realities” 
J. R. R. Tolkien  
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1. Introduction 
 
1.1. The Joint 
Muscles pull on bone to make them move, but movement would be impossible without joints. 
Joints allow the skeleton to be flexible, enabling it to bend in certain locations that in turn allows 
movement at different degrees around those locations while, simultaneously, providing protection 
for the same [1]. A joint, or articulation, is an anatomical location where two or more bones come 
together and can be classified into three groups depending on the type of structures that binds these 
bones: fibrous, cartilaginous and synovial [1, 2]. 
In a fibrous joint bones are united by a fibrous, collagen rich, connective tissue and have no joint 
cavity. This type of joint can be found between the bones of the skull, for instance. Cartilaginous 
joints are similar to fibrous joints but, in their turn, they are connected by cartilage, being it hyaline 
or fibrocartilage. An example of a cartilaginous joint is the manubriumsternal joint (between the 
manubrium and sternum). Synovial joints are more complex than fibrous and cartilaginous joints. In 
a synovial joint bones are not directly joined, the articular extremities of the bone are encapsulated 
in a synovial cavity by dense connective tissue and often strengthened by complementary ligaments 
as shown in Figure 1-1. An example of a synovial joint is the acromioclavicular joint (between the 
acromium and the clavicle) [1, 2]. 
 
Figure 1-1 – Structure of a synovial joint. Adapted from [1]. 
 
The different constituents of a synovial joint are described in detail below: 
1. Joint capsule – composed by an outer fibrous capsule that may be attached to auxiliary 
ligaments, and an inner synovial membrane, also known as synovium, that secretes the 
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synovial fluid and contains two cell types, macrophage-like synoviocytes (MLS) and fibroblast-
like synoviocytes (FLS). The joint capsule stabilizes and provides protection to the 
articulation; 
2. Joint cavity – space comprised by the joint capsule and filled with synovial liquid. This liquid, 
containing hyaluronic acid and lubricin, provides lubrication, shock absorption and 
nourishment to the joint and bones; 
3. Articular cartilage – hyaline cartilage covers the bone inside the synovial cavity increasing 
shock absorption and reducing friction between bones during movements [1-3]. 
Joints can also be classified according to the type and degree of movement allowed: i) 
synarthrosis, when they allow little to no mobility, ii) amphiarthrosis, when they allow slight mobility, 
and iii) diarthrosis, when they allow free mobility. This functional characterization is associated with 
their structural classification, thus most synarthrosis joints are fibrous joints, most amphiarthrosis 
joints are cartilaginous joints and all diarthrosis are synovial joints [1, 2]. 
 
1.2. Rheumatoid Arthritis 
1.2.1. The Disease 
Rheumatoid arthritis (RA) is a chronic systemic inflammatory disease of uncertain cause that 
affects 1% of the population of the developed world, being more common among women than men. 
RA usually develops in the fourth and fifth decade of life, with 80% of the total cases occurring 
between the ages of 35 and 50 [4-7]. It is also theorized that some individuals are more genetically 
susceptible to contract this disease than others [6, 8]. RA is often induced by an external agent (like 
cigarette smoking, infection or trauma) that triggers an autoimmune reaction, leading to synovial 
hypertrophy and chronic joint inflammation along with potential for extra-articular manifestations 
[4-8]. 
RA is usually a clinical syndrome spanning several disease subsets, which all lead towards a final 
common pathway in which persistent inflammation and associated damage to articular cartilage and 
underlying bone are present (figure 1-2). The primary symptoms of RA are pain, stiffness and swelling 
of the joints resulting in impaired physical function and movement. These symptoms are often 
accompanied by inherent symptoms such as fever and malaise. Although there are several associated 
mechanisms that trigger RA inflammation, the exact pathway that leads to it was not yet been 
determined [4-8]. 
The primary inflammation of RA starts in the synovium. An external factor induces the 
overproduction of TNF-α by MLS and FLS. In response, the tissue of the synovial lining enters 
hyperplasia, as a result of MLS and FLS proliferation and accumulation. This increased number of 
synoviocytes leads to an even higher production of TNF-α and an overproduction of many pro-
inflammatory cytokines such as interleukin-6 (IL-6) and interleukin-1 (IL-1) that drive and maintain 
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the persistent inflammation and induce joint destruction, by increasing the production of matrix 
metalloproteinases (MMPs) and activating osteoclasts [4, 6, 7, 9]. It has also been observed that, in 
RA, FLS show abnormal behavior and may spread to other joints, supporting hypothesis that RA starts 
in joints [6]. 
 
Figure 1-2 – Pathogenesis of RA: synovial and systemic inflammation. Adapted from [7]. 
 
Autoantibodies also play an important role in RA by wrongly targeting the body’s own molecules 
as foreign or pathogenic. The main autoantibodies usually found in RA are rheumatoid factors 
(primarily IgM and IgA rheumatoid factors) and antibodies directed against citrullinated peptides 
(ACPA) located in the outer cellular membrane. In fact, 50-80% of all patients present at least one of 
these antibodies [6, 8]. It has also been registered that the presence of ACPA leads to histologically 
different types of RA, patients with ACPA (ACPA-positive) tend to have more lymphocytes in the 
synovial tissue; on the other hand, patients without ACPA (ACPA-negative) have increased fibrosis. 
Additionally, ACPA-positive RA is associated with increased joint damage and low remission rates [6]. 
 
1.2.2. Diagnosis, Management and Treatment 
Early diagnosis and treatment have been recognized as essential for improving clinical outcomes 
in patients with rheumatoid arthritis. RA diagnosis is usually achieved by bloods tests or imaging 
techniques such as X-rays or magnetic resonance imaging (MRI) [4-6, 10]. However, diagnosis is 
somewhat difficult in the early stages of the disease since diagnostic criteria were developed from 
data obtained in patients with established rheumatoid arthritis, and therefore, are not readily 
applicable [11, 12]. 
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In particular, MRI as demonstrated a greater sensitivity to early RA signs when compared to clinical 
examination or traditional radiology imaging. MRI allows for a direct visualization of the joint and 
enables the identification and analysis of the earliest histological and physiological alterations, 
making it a promising tool for an early RA diagnosis [5, 10-12].  
Currently, there is no cure for RA, but some treatments are able to improve symptoms and hinder 
disease progression. These therapies aim to minimize symptoms such as articular pain and swelling, 
prevent bone erosion and deformity, and maintain joint functionality for daily activity. The best 
results with these treatments are obtained when they are initiated early and aggressively [4-6, 11, 
13, 14]. 
Disease management is achieved primarily by using two main classes of medication: i) analgesics 
and non-steroidal anti-inflammatory drugs (NSAIDs) that lessen joint pain and stiffness, and disease-
modifying anti-rheumatic drugs (DMARDs) that reduce joint swelling and pain, decrease acute-phase 
markers, limit progressive joint damage and improve function, by facilitating movement [5-7, 9, 13, 
14]. 
The dominant DMARD in RA management is methotrexate (MTX), due to its proven efficacy, safety 
profile and low cost. MTX is an analogue of folic acid that ultimately disrupts cellular folate 
metabolism by inhibiting its target enzyme, the di-hydrofolate reductase. This drug seems to exert 
its anti-inflammatory effects by acting at different levels of the pathophysiological signaling cascade, 
directly inhibiting proliferation, pro-inflammatory cytokine production and inducing apoptosis in cells 
involved in immune and inflammatory reaction. These combined effects explain the overall anti-
inflammatory action of MTX in the sustained management of RA [5, 6, 9]. 
New therapies are also been studied that consider the use of biological agents that target TNF-α 
and kinase receptors, in an attempt to disrupt RA signaling pathways, as well as the use of 
glucocorticoids to diminish synovial inflammation [6, 7, 13-16]. Despite recent developments and 
intensive research in RA, there is no definitive cure for the disease. Additionally, most of these 
treatments are also not targeted, leading to drug accumulation in undesired locations that may cause 
complications [6, 7, 13, 14]. 
 
1.3. Nanomedicine  
Nanotechnology is the understanding and manipulation of materials whose dimensions range 
between 1-100 nm and has been in the forefront of much research in the past decades. Although 
nanotechnology comprises dimensions between 1-100 nm other systems consider materials with more 
than 100 nm to be applications of nanotechnology [17]. Traditionally, nanoparticles (NPs) are made 
of metals, ceramics and inorganic semiconductors. However, NPs can also be made of organic 
polymers, colloids or biomolecules, including DNA, proteins and lipids. This alternative approach is 
known as soft nanotechnology. This research led to innumerous applications, in particular the 
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application of this technology to medicine gave rise to nanomedicine [18-23]. As a consequence of 
the intensive work done in the area of nanotechnology, biocompatible colloidal systems, such as 
matrix NPs, micellar systems and conjugates have been developed. These systems enable 
nanomedicine applications for drug delivery and tissue regeneration strategies [17, 20, 22, 24]. 
Nanomedicine allowed the development of many drug delivery systems. Due to the side-effects 
of many drugs, nanoparticulate drug delivery systems were designed in order to achieve fewer 
complications. The main objective of using colloidal drug delivery systems is the reduction of systemic 
side-effects and maintenance of appropriate drug concentration in the required place. In these 
systems NPs are more interesting when compared with microparticles, since they possess a greater 
cell uptake, which is desirable when the drug is intended to penetrate the cellular membrane [20, 
22, 24, 25]. 
The possibility of NP multi-functionalization opens the path for a novel and widespread medical 
applications based on nanomedicine strategies. (Figure 1-3).  NPs have the potential to carry 
therapeutic and/or imaging agents, for theranostic applications. They can be conjugated to a specific 
ligand, such as antibodies, to target a specific tissue or organ or facilitate cellular penetration. They 
can also be used to avoid/bypass bio-barriers and macrophage uptake, by coating the NP with 
polyethylene glycol (PEG), for example [26-36]. 
 
Figure 1-3 – Schematic representation of a multifunctional NP. Adapted from [17]. 
 
Although nanomedicine has successfully achieved targeted drug delivery, this would not be 
possible without the prior identification of novel and specific cell surface markers. These markers 
are overly expressed in specific tissues or in specific disease-infected tissues and allow an accurate 
targeting to the tissues in question [28, 30-34, 37].   
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The multi-functionalization of NPs also offers new opportunities for nanomedicine applications, 
as it allows a simultaneous conjugation of therapeutic and diagnostic agents in a single approach. In 
the light of the new nanomedicine advancements, new theranostic approaches are being studied in 
order to provide more efficient diagnostic, treatment and monitoring of many diseases [21, 22, 32]. 
Nanomedicine approaches have been studied using several different NPs, like polymeric NPs [26, 
29], magnetic NPs [27] and lipid NPs [28, 31, 38]. For the purposes of this work, lipid NPs, in particular 
solid lipid nanoparticles (SLNs), will be used. They will be more thoroughly discussed in the following 
sections. 
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2. State of the Art 
 
In biology, naturally occurring nanostructures have been a source of inspiration for new 
nanotechnological designs and hybrid-nanostructures made of biological and non-biological, organic 
and inorganic building blocks. Lipids, with their amphiphilicity, diversity of head and tail chemistry, 
and antifouling properties that block nonspecific binding to lipid-coated surfaces, provide a powerful 
toolbox for nanotechnology [18, 19, 21-23]. 
 
2.1. Lipid Nanotechnology 
The first attempt to incorporate lipophilic drugs in lipid droplets was the parenteral fat emulsion 
method developed in the 1960s, which is still widely used in the clinic for the parenteral application 
of poorly water-soluble drugs [23, 39]. But it was only in 1991 that the first generation of lipid NPs, 
the SLNs, were developed [23, 39-41].  
Lipids possess desirable properties for applications in nanomedicine. They are biocompatible, 
biodegradable and well tolerated all over the body making them very versatile when considering 
various administration routes. Since the lipids used in the production of lipid nanoparticles naturally 
exist in the body, their degradation products are easily metabolized by the organism. Therefore lipid 
nanoparticles for drug delivery applications are associated to little or none systemic cytotoxicity [30, 
31, 37, 42-45]. 
When designing a lipid nanoparticle for drug delivery applications three main types of particle 
models can be considered: i) solid solution with the drug molecularly dispersed, ii) lipid rich core 
with drug-enriched shell, and iii) lipid shell with drug-enriched core, as illustrated in figure 2-1. The 
first model allows for a constant release of drug, as the second and third models enable an immediate 
and a controlled release, respectively [25, 39-41]. 
Lipids also have the ability to self-assemble when in aqueous solution into different structures, 
depending on the lipids used. This enables fast and simple production methods that may also help to 
lower the cost of NP production and facilitate scale-up of the method used [23, 39, 46, 47]. 
As previously stated, different types of lipids are used to produce different types of lipid 
nanoparticles. The three main types of lipid nanoparticles are: i) liposomes and micelles, ii) SLNs, 
and iii) nanostructured lipid carriers (NLCs) [23, 25, 39, 41, 48, 49]. These different types of lipid 
nanoparticles are described in detail bellow. 
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Figure 2-1 - Three drug incorporation models (solid solution model (left), core-shell models with drug-
enriched shell (middle) and drug-enriched core (right)). Adapted from [40]. 
 
2.1.1. Liposomes and Micelles 
Liposomes and micelles are small NPs formed by the self-assembly of amphipilic lipids in aqueous 
environment. Liposomes are bilayer vesicles, that may be uni- or multi-lamellar, while micelles are 
monolayer aggregates (figure 2-2) [23, 49-51]. In liposomes the polar heads of the lipids (hydrophilic) 
are located outwards in the bilayer, faced towards the inner aqueous core and the outer environment. 
This aqueous core represents an advantage in the use of liposomes for drug delivery as both 
hydrophilic and lipophilic drugs can be loaded inside the NP, in the core and inside the bilayer 
membrane of the NP, respectively. In micelles, on the other hand, the polar heads surround the entire 
lipid aggregate and the apolar tails (hydrophobic) are turned inwards, resulting in a more dense solely 
hydrophobic structure [49-51]. 
 
Figure 2-2 – Schematic representation of a liposome (left) and a micelle (right), both transversely sectioned. 
Adapted from [50]. 
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Both liposomes and micelles may be derived from the hydration of lipid films or from disrupting 
cellular membranes. However they only form if a specific lipid concentration is achieved in the 
medium, i.e. if the critical micelar concentration (CMC) is reached [23, 49-51]. 
A key parameter in determining whether liposomes or micelles will be formed is the lipid 
geometry, since it has great influence in the packing and arranging of the lipids (figure 2-3). 
Cylindrical lipids, such as phosphatidylcholine, tend to arrange themselves to form lipid bi-layers, 
favoring liposomal structures, whereas conical lipids, such as lysophosphatidylcholine, tend to form 
micelles [49-51]. Some lipids, such as arachidonic acid, are known to have an inverted cone geometry 
and are capable of forming inverse micelles, relying on surfactants to stabilize the hydrophobic tails 
of the lipid [51, 52]. 
 
Figure 2-3 – Geometry of phosphatidylcholine (pink), lysophosphatidylcholine (blue), arachidonic acid 
(green) and their tendency to self-assemble. Adapted from [52]. 
 
As previously described, liposomes and micelles are usually produced by self-assembly in aqueous 
environment and can be easily functionalized recurring to the polar groups existing on their surface. 
This functionalization can be performed either before or after particle production. It is also possible 
to incorporate lipids that “react” to specific environments into the lipid layer, making the liposome 
or micelle responsive to certain conditions, such as low pH [23, 49-51]. 
Liposomes have found several different applications as NP-based drug delivery systems such as 
increase skin penetration after topical administration for meloxicam delivery [53], multiple 
modification for integrin targeting in triple-negative breast cancer [54] and coating with 
thermosensitive polymers for ultrasound-mediated drug delivery [55]. 
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2.1.2. Solid Lipid Nanoparticles 
SLNs are submicron sized nanoparticles, in the range of 50-1000 nm, composed of physiologically 
tolerated lipid components which are in a solid state at room temperature. These NPs consist of a 
solid lipid matrix that allows the encapsulation and protection of drugs against degradation and 
modification of the drug release profile [23, 39-42]. Several different lipids can be used to compose 
the matrix that has to be stabilized by a surfactant (emulsifier) or combination of surfactants that 
can highly influence the properties of the resulting particles [30, 43, 46-48, 56]. 
SLNs are seen as an alternative carrier system to polymeric NPs which is identical to oil-in-water 
(o/w) emulsions, but where the polymer of the emulsion is replaced by a solid lipid, shown in figure 
2-4. Thanks to their structure and composition SLNs combine many of the advantages of polymeric 
nanoparticles, fat emulsions and liposomes [23, 25, 39, 41, 57, 58]. SLNs allow a controlled release 
of the encapsulated drug, with excellent biocompatibility and high drug content, increased stability 
and bioavailability of the bioactive compounds. These NPs are also capable of incorporating 
hydrophilic and hydrophobic drugs and can be easily subjected to commercial sterilization 
procedures. However there are a few disadvantages associated with SLNs such as high water content 
in the dispersions and the possible expulsion of drug during storage due to a shift in crystallization 
forms [23, 25, 39-41, 57, 59]. 
 
Figure 2-4 – Schematic representation of the structure of a solid lipid nanoparticle (SLN). Adapted from [41]. 
 
SLNs can be produced by several different methods from solid lipids, emulsifying agents and 
water/other solvent. The two most commonly used methods are High Pressure Homogenization (HPH), 
hot or cold, and w/o/w double emulsion [23, 41, 46, 47, 56]. Both methods are relatively simple and 
fast, at a relatively low cost, require no special solvents and easily allow scale-up production. HPH 
may cause drug degradation (high temperatures in hot homogenization) or coalescence (by high 
pressure) but require no organic solvents of any kind. Whereas double emulsion requires organic 
solvents but allows the encapsulation of thermo-sensible drugs [46, 47, 56]. 
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SLNs have been used for several different applications by different groups such as to encapsulate 
SPIONs for controlled drug delivery [60], delivery systems of camptothecin to the brain by intravenous 
administration [31], oral administration of insulin after modification with stearic acid-actaarginine 
[61] and coated with chitosan in order to increase drug bioavailability after oral administration [37]. 
The functionalization of SLNs may be complicated because solid lipids that constitute the NPs 
possess few exposed polar groups, which are the targets of most functionalization methods [23, 40, 
41, 48]. However some success has achieved by using electrostatic layer-by-layer assembly [44, 45], 
by functionalizing to surfactant instead of the lipids themselves [33, 62], by coating the surface of 
positively-charged SLNs with polymeric material like chitosan and then functionalizing the polymer 
[37] and by embedding phospholipids in the SLN and functionalizing them [33, 38]. 
 
2.1.3. Nanostructured Lipid Carriers 
NLCs are similar to SLNs in several aspects and due to this share many of the same properties and 
advantages as them (described in the previous section). The main difference between NLCs and SLNs 
is that the first are produced from a blend of liquid and solid lipids, whereas the latter are produced 
solely of solid lipids [23, 25, 39, 59]. This compositional variation alters the structure of NP, SLNs 
tend to form perfect crystals while NLCs inhibit the crystallization process and produce imperfections 
in the lattices. This mixture of lipids in NLCs can be tailored in order to achieve a pretended 
nanostructure with the goal to better accommodate the drug or to alter its release profile. NLCs were 
developed in order to surpass the SLNs potential drug expulsion caused by crystalline form shift, this 
was achieved by producing a NP without a perfect crystallization of the lipid matrix, as previously 
described [23, 25, 39]. 
Three main types of NLCs have been described regarding their structure: i) imperfect type, ii) 
amorphous type and iii) multiple type, [25, 39, 41, 59] as shown in figure 2-5.  
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Figure 2-5 – Schematic representation of the three types of NLCs: imperfect type (top), amorphous type 
(middle) and multiple type (bottom). Adapted from [59]. 
 
Imperfect type NLCs have an imperfect structured solid matrix, this is achieved by mixing 
different lipids (liquid and solid) that cause imperfections in the crystallization of the lipid matrix. 
These imperfections are what accommodate the drug, additionally mixing small of chemically 
different liquid lipids increases incompatibility, consequently increasing the number of imperfections 
and the drug payload. Amorphous type NLCs possess a solid amorphous matrix without any specific 
structure that prevents drug expulsion caused by crystallization form shift since the matrix is 
amorphous and not crystalline. This is achieved by mixing solid lipids with special lipids such as 
isopropylmyristate. Multiple type NLCs consist of multiple oil in fat in water (O/F/W) double 
emulsions, where the drug is solubilized in the lipophilic phase and its solubility decreases during 
cooling and storage. Many drugs have higher solubility in liquid lipids than in solid lipids and therefore 
a higher payload can be obtained using this type of NLC [25, 39, 59]. 
NLCs have been proposed for applications of different natures such as an attempt to increase 
cellular uptake by modifying the NLCs with chitosan hydrochlorides [63], optimization of intranasal 
delivery of artemether [64] and to try and enhance in vitro activity by surpassing drug resistance of 
Doxorubicin and Ducosahexaenoic acid in cancer cells [65]. 
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2.2. Nanoparticle Functionalization 
Nanomedicine has brought a new tool for medical applications laid on the ability to multi-
functionalize the drug delivery systems for innumerous purposes. These functionalization can be 
obtained by different methods, depending on the type of NP and its composition, and designed for 
different ends, both of which are described in the following sections. 
 
2.2.1. Functionalization Methods 
NP functionalization can be achieved by four main approaches (shown in figure 2-6): i) 
electrostatic attachment, ii) covalent linkage to a NP ligand, iii) attachment to a co-factor bound to 
the ligand or the NP itself, and iv) direct covalent linkage to the NP surface [27, 33, 34, 66, 67].  
 
Figure 2-6 – Schematic representation of the four main approaches for NP functionalization: (a) electrostatic 
attachment, (b) covalent attachment to ligand, (c) attachment to a co-factor and (d) covalent attachment 
to the NP surface. Adapted from [66].  
  
Electrostatic attachment is the simplest approach that requires no type of chemical reaction 
consisting of an electrostatic adsorption between differently charged NP and biomolecule. In order 
to perform this method the surface of the NP has to be electrically charged (negative or positive) so 
that a biomolecule with the opposite charge can be adsorbed. This method is already routinely used 
as an electron dense marker in histology [27, 33, 66, 67].  
Another general method for NP functionalization is covalent linking to a NP ligand, occurring when 
a biomolecule (usually a protein or peptide) is able to react with a ligand to form a covalent bound. 
This linkage is very stable and resistant and is also widely used for surface modification in several NPs 
applications. The most commonly used functional groups for this reaction are amine and carboxylic 
acid groups. The method of direct covalent linkage is very similar to this method but instead of the 
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biomolecule reacting with a functional group on the end of the ligand it reacts with one directly on 
NP surface [33, 66, 67]. 
Alternatively, NP functionalization can be achieved attachment to a co-factor. This is usually 
performed by using specific labeling strategies of bioconjugation: firstly a labeling molecule is 
attached to the NP surface or NP ligand and after this a second molecule (linked to the desired 
biomolecule) with great affinity for the label is added creating a stable linking complex. The most 
commonly used linkage is biotin-streptavidin that allows for up to 4 biotin molecules to be linked to 
1 streptavidin and also has a nearly covalent dissociation constant. Note that the antibody conjugation 
falls into this category of linkage, since the antibody will be linked to the NP and recognize specific 
epitopes binding only to them [33, 66, 67]. 
 
2.2.1.1. Lipid NPs Functionalization 
 The functionalization of lipid NPs is generally obtained by covalent linkage, directly to the 
surface or an attached ligand, or by bioconjugation methods. These methods usually imply the use of 
a lipid “anchor” with an amine, phosphate or carboxylic acid in the head portion, since not all lipids 
possess functional groups that are capable of functionalization reactions. This lipid anchor is usually 
pre-functionalized and can be incorporated during NP synthesis or post-synthesis. 
Several groups have been able to successfully functionalize SLNs for innumerous nanomedicine 
applications using the previously described methods, or similar methods with slight variations, as 
shown in table 2-1. 
 
2.2.2. Functionalization Purposes 
A NP functionalization can be performed to achieve a variety of purposes, Table 2-1 shows some 
examples of SLNs with functionalization for specific applications. Note that the Table 2-1 only shows 
SLN applications because they are the focus of this work, but the applications described in this section 
are transversal to all NPs.  Most NP surface functionalization aim to: i) decrease identification and 
elimination by the immune system in the blood stream, ii) enable specific targeting of the NP to the 
pretended tissue or organ, or iii) facilitate the entry of the NP into the cells [26-29, 32-34, 67]. 
The coating of the NP with long chain hydrophilic polymers allows the creation of stealth NPs that 
are not easily recognized by the immune system and therefore have increased circulation time [26, 
29, 32, 33]. The use of polyethylene glycol (PEG) chains has been highly described for this type of 
application and has demonstrated excellent efficacy [26, 29]. 
Some molecules have the ability to permeate a cell by using specific selective channels in the 
cellular membrane. These channels could be used as an advantage to increase NP uptake by placing 
the same molecules in the surface of the NP [33, 34, 66, 67]. This technique has already been 
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successfully applied, for instance, in the coating NP with polysorbate 80 to help penetrate the Brain-
Blood-Barrier (BBB) [30]. 
NP surface coating with targeting molecules is the most common application of NP surface 
functionalization, as the molecules are capable of recognizing specific cell membrane markers and 
attaching only to them, enabling highly specific cell targeting [33, 34, 66, 67]. The use of antibodies 
as targeting agents is widely described in the literature for targeted drug delivery for example [33, 
34]. 
 
Table 2-1 – Applications of some specific functionalized SLNs. 
Functionalization Application Reference 
PEG coating Immune avoidance [33] 
Polysorbate 80 Brain delivery [30] 
Poly-L-Lysine Transendothelial Permeation [44] 
Polystyrene Sulfonate Transendothelial Permeation [44] 
Polyacrylic Acid Transendothelial Permeation [44] 
Poly-L-Lysine Transendothelial Permeation [68] 
Chitosan coating Acidic pH resistance [37] 
Heparin Natural Killer cells targeting [45] 
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3. Rationale and Strategy of the Thesis 
 
In this work, an approach to attempt targeted therapy and simultaneous imaging is proposed. This 
study aims to develop a targeted theranostic system for intravenous administration, consisting of the 
encapsulation of MTX (RA therapeutic drug) and SPIONs (MRI contrast agent) within SLNs. These SLNs 
are functionalized with a monoclonal antibody (mAb) against the MLS specific cell surface receptor, 
CD64. A representation of the strategy is shown in figure 3-1. 
This work was divided in to two separate phases. Firstly a research on the fundamental basics and 
the current state of the art was performed as well as a planning of the work to be done in the 
experimental phase of the work. This phase took place during the first semester of the 2013/2014 
school year, from October to January. The second place was accomplished during the second semester 
of the same school year, from February to June, and consisted mainly of experimental research work, 
conducted in the department of Chemical Sciences of the Faculty of Pharmacy, University of Porto. 
Considering the experimental research work, the first step was NP production and 
characterization. After the process of optimization, four different formulations were prepared: i) 
cetyl palmitate SLNs, ii) MTX-loaded cetyl palmitate SLNs, iii) SPIONs-loaded cetyl palmitate SLNs and 
iv) MTX- and SPIONs-loaded cetyl palmitate SLNs. All of these formulations were then extensively 
characterized in terms of NP diameter, polydispersion, zeta potential and morphology. The NP 
content of MTX and SPIONs were also determined. The four formulations were also conjugated with 
an antibody and its presence was verified and quantified. This extensive characterization enabled 
comparison of NPs properties and the assessment of each of the formulation’s components effect on 
those properties. Finally in vitro assays were performed, using the monocytic cell line THP-1, in order 
to assess cellular viability and NP’s cytotoxicity.  
 
Figure 3-1 – Schematic representation of the proposed strategy for theranostic application in RA.  
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4. Materials and Methods 
 
4.1. Materials 
The lipids cetyl palmitate and Witepsol E85 were gently provided by Gattefossé (Saint Priest 
Cedex, France) and Sasol (Joanesburgo, Gauteng, South Africa), respectively. Stearic acid was 
purchased from Merck (© Merck KGaA, Darmstadt, Germany). MTX was obtained by courtesy of Excella 
(Excella GmbH, Feucht, Germany).  Iron Oxide Nanocrystals (10 nm) coated with oleic acid and 
dispersed in chloroform (25 mg/mL) were kindly provided by Ocean Nanotech (Ocean Nanotech Inc., 
Springdale, AR, USA). Anti-Human CD64 (Fc gamma Receptor 1) antibody solution (1 mg/mL) was 
purchased from eBioscience (eBioscience Inc., San Diego, CA, USA). LDH Cytotoxicity Detection Kit 
was from Takara Bio (Takara Bio Inc., Shiga, Japan). Twee 60, dimethyl  sulfoxide  ACS  reagent 
≥99.9%  (DMSO),  dichloromethane  (ACS  reagent,  ≥99.5%  contains  50  ppm  amylene  as  stabilize),  
ethyl acetate (ACS reagent, ≥99.5%), 2-morpholinoethanesulfonic acid low moisture content, ≥99% 
(MES), 1-ethyl-3-(3-dimethylaminopropyl) carbodiimide hydrochloride purum, ≥98.0% (EDC), N-
hydroxysulfosuccinimide 98% (NHS), Thiazolyl Blue Tetrazolium  Bromide 98% (MTT), Triton™ X-100 
for molecular biology, Trypan Blue powder and phorbol 12-myristate 13-acetate (PMA) were  
purchased  from  Sigma-Aldrich  (St. Luis, MO, USA).  Dulbecco’s  Modified  Eagle’s  Medium  (DMEM),  
Dulbecco’s  phosphate  buffer  saline  10x  pH  7.4  (PBS),  fetal  bovine  serum (FBS), Penicillin-
Streptomycinm  and  Fungizone ® Antimycotic were  purchased  from  Gibco® (Invitrogen Corporation, 
Paisley, UK). Aqueous solutions were prepared with double-deionized water (Arium Pro, Sartorius AG, 
Göttingen, Germany). THP-1 (ATCC® TIB-202TM) cells were generously provided by Professor Susana 
Santos and Doctor Marta Freitas, INEB 
 
4.2. Methods 
4.2.1. Preparation of Multifunctional Nanoparticles 
4.2.1.1. Optimization of Nanoparticle production method 
In the first attempt of NP production both cetyl palmitate and Witepsol E85 were used in an 
organic solvent-free emulsification-sonication method that combined high shear homogenization and 
ultra-sonication. As standard procedure, 500 mg of solid lipid (cetyl palmitate and Witepsol E85) and 
100 mg of surfactant (Tween 60) were heated to 70ºC, in order to fuse the lipids. After the lipids 
were totally fused, 4.400 mL of water at 70ºC were added to the fused lipid-surfactant mixture, and 
the resulting solution was immediately homogenized with a high-shear homogenizer (YSTRAL GMBH 
X10/20-E3, Ballrechten-Dottingen, Germany) for 30 seconds at 12000 rpms to produce a lipid-in-water 
micro-emulsion. This micro-emulsion was afterwards re-homogenized using a probe-type sonicator 
(model VCX-130 with a VC 18 probe, Sonics&Materials Inc., Newtown, CT, USA) for 5 minutes at 80% 
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amplitude to produce the NPs. The resulting NP suspension was stored in glass flasks at room 
temperature until further use. 
Table 4-1 - Physicochemical properties of the NP formulations. Size, PdI and Zeta potential for all the 
formulations considering both Witepsol E85 and cetyl palmitate SLNs for different homogenization and 
sonication times. 
Lipid used in 
SLN 
Homogenization 
time (sec) 
Sonication 
time (min) 
Size (nm) PdI 
Zeta Potential 
(mV) 
Witepsol E85 30 5 798.5 ± 16.8 0.372 ± 0.004 -34.27 ± 0.66 
Witepsol E85 30 10 954.5 ± 3.40 0.372 ± 0.016 -27.14 ± 0.96 
Witepsol E85 30 15 762.9 ± 37.5 0.350 ± 0.022 -28,04 ± 1,05 
Witepsol E85 60 5 781.1 ± 125.8 0.334 ± 0.019 -22.39 ± 0.87 
Witepsol E85 60 10 639.3 ± 68.1 0.346 ± 0.003 -26.03 ± 0.64 
Witepsol E85 60 15 338.3 ± 9.6 0.334 ± 0.026 -29.02 ± 1.14 
Witepsol E85 120 5 729.2 ± 68.3 0.388 ± 0.006 -28.31 ± 0.76 
Witepsol E85 120 10 661.9 ± 30.6 0.333 ± 0.030 -28.16 ± 0.95 
Witepsol E85 120 15 536.0 ± 21.6 0.379 ± 0.004 -21.99 ± 2.69 
Cetyl Palmitate 30 5 466.4 ± 16.7 0.248 ± 0.019 -36.67 ± 0.78 
Cetyl Palmitate 30 10 333.0 ± 8.2 0.280 ± 0.010 -36.18 ± 0.75 
Cetyl Palmitate 30 15 471.2 ± 7.8 0.286 ± 0.010 -36.35 ± 0.92 
Cetyl Palmitate 60 5 455.7 ± 3.6 0.277 ± 0.008 -36.52 ± 0.83 
Cetyl Palmitate 60 10 426.2 ± 2.2 0.277 ± 0.004 -34.02 ± 0.69 
Cetyl Palmitate 60 15 430.0 ± 5.9 0.247 ± 0.011 -33.57 ± 1.86 
Cetyl Palmitate 120 5 397.3 ± 6.3 0.234 ± 0.015 -31.71 ± 1.04 
Cetyl Palmitate 120 10 437.3 ± 7.1 0.252 ± 0.010 -29.20 ± 1.01 
Cetyl Palmitate 120 15 415.3 ± 7.1 0.246 ± 0.017 -37.13 ± 0.49 
 
 In an attempt to better understand the effects of the homogenization process in NPs properties 
new NPs were prepared, using the same method that was previously described but increasing both 
homogenization and sonication times. It was found that increasing the homogenization times (30 
seconds, 1 minute and 2 minutes) or the sonication times (5 minutes, 10 minutes and 15 minutes) 
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resulted in little changes to the NP properties and so no alterations were done to the original method 
(table 4-1).  
To later facilitate NP functionalization the number of available functional groups, in particular 
carboxylic terminal groups, on the NP surface should be increased as much as possible. In order to 
achieve, this the addition of a fatty acid was proposed. Fatty acids have long hydrophobic chains that 
enable an easy integration into the SLN matrix and possess a terminal carboxylic acid group that could 
be used for antibody conjugation. Two fatty acids were chosen and assessed (Table 4-2) for this: i) 
stearic acid (an 18-C long saturated fatty acid) and ii) oleic acid (an 18-C long unsaturated acid fatty 
acid). The results showed that the NP formulation with more promising characteristics were composed 
of cetyl palmitate and stearic acid and, therefore, the other formulations were discarded at this 
point. To further optimize the cetyl palmitate/stearic acid formulation several proportions of acid 
were used (2.5%, 5%, 7.5% and 10%) and best properties were obtained using 7.5% (regarding total 
formulation weight) of stearic acid (Table 4-3). 
Table 4-2 - Physicochemical properties of the NP formulations. Size, PdI and Zeta potential for all the 
formulations considering both Witepsol E85 and cetyl palmitate SLNs with oleic and stearic acid. 
Lipid used in SLN Fatty acid Size (nm) PdI Zeta Potential (mV) 
Witepsol E85 Oleic acid 607.0 ± 18.1 0.358 ± 0.008 -41.10 ± 3.10 
Witepsol E85 Stearic acid 660.9 ± 56.0 0.309 ± 0.020 -36.93 ± 1.42 
Cetyl palmitate Oleic acid 426.6 ± 150.3 0.241 ± 0.025 -39.08 ± 1,21 
Cetyl palmitate Stearic acid 408.6 ± 16.4 0.229 ± 0.031 -41.11 ± 0.35 
Table 4-3 - Physicochemical properties of the NP formulations. Size, PdI and Zeta potential for all the 
formulations considering cetyl palmitate SLNs with stearic acid at different %. 
Lipid used in SLN Stearic acid % Size (nm) PdI Zeta Potential (mV) 
Cetyl palmitate 2.5% 607.0 ± 18.1 0.358 ± 0.008 -28.84 ± 2.33 
Cetyl palmitate 5.0% 660.9 ± 56.0 0.309 ± 0.020 -34.58 ± 1.50 
Cetyl palmitate 7.5% 426.6 ± 150.3 0.241 ± 0.025 -40.04 ± 0.96 
Cetyl palmitate 10.0% 408.6 ± 16.4 0.229 ± 0.031 -39.62 ± 1.45 
 
The selected formulation (cetyl palmitate with 7.5% stearic acid) was still presenting dimensions 
that were too large for the pretended application. On a first attempt to reduce NP diameter the NP 
suspension were filtrated (using disposable syringes and cellulose filters with several pore sizes). 
Filtration greatly improved NP diameter but it was shown to retain a large amount of NPs in the 
filters, causing a large amount of mass loss that would be translated in the future to large drug loss. 
Because of this issue filtration was discarded from the process. In another attempt to reduce NP size 
a decrease in total lipid quantity (600 mg to 400 mg of total formulation) and an increase in the 
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lipid/surfactant proportion (16%, 20%, 25%, 30% and 35% of the formulation total) was considered (the 
latter results can be observed in Table 4-4). The formulation that presented the best NP 
characteristics was composed of 400 mg of total mass with theoretical 35% of surfactant. 
Table 4-4 - Physicochemical properties of the NP formulations. Size, PdI and Zeta potential for all the 
formulations for cetyl palmitate SLNs with surfactant at different %. 
Lipid used in SLN Surfactant (%) Size (nm) PdI Zeta Potential (mV) 
Cetyl palmitate 16% 434.2 ± 12.8 0.284 ± 0.015 -37.65 ± 1.31 
Cetyl palmitate 20% 340.3 ± 5.3 0.231 ± 0.007 -49.78 ± 0.70 
Cetyl palmitate 25% 255.6 ± 4.0 0.206 ± 0.008 -47.27 ± 1.19 
Cetyl palmitate 30% 214.4 ± 3.6  0.200 ± 0.008 -46.78 ± 0.61 
Cetyl palmitate 35% 164.6 ± 1.9 0.189 ± 0.008 -44.33 ± 1.30 
 
4.2.1.2. Definitive Nanoparticle production method 
SLNs composed of cetyl palmitate and stearic acid were prepared by an organic solvent-free 
emulsification-sonication method that combined high shear homogenization and ultra-sonication 
(figure 4-1). As standard procedure, 230 mg of cetyl palmitate, 30 mg of stearic acid and 140 mg of 
Tween 60 were heated to 70ºC (temperature above the fusion point of all the lipids in the mixture), 
in order to fuse the lipids. 4.400 mL of water at 70ºC was added to fused lipid-surfactant mixture and 
the resulting solution was immediately homogenized with a High-shear Homogenizer (YSTRAL GMBH 
X10/20-E3, Ballrechten-Dottingen, Germany) for 30 seconds at 12000 rpms to produce a lipid-in-water 
micro-emulsion. This micro-emulsion was afterwards re-homogenized using a probe-type sonicator 
(model VCX-130 with a VC 18 probe, Sonics&Materials Inc., Newtown, CT, USA) for 5 minutes at 80% 
amplitude to produce the NPs. The resulting NP suspension was stored in glass flasks at room 
temperature until further use. 
The encapsulation of both MTX and SPIONs was achieved during the production method [35]. 4 mg 
of MTX were added prior to the lipid fusing and dissolved, as much as possible, in fused solid lipid + 
surfactant mixture. 40 µl of SPION dispersion were added after the lipid fusion and before the addition 
of the water.  
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Figure 4-1 – Schematic representation of the NP preparation procedure. 
 
Four different formulations were prepared: i) SLN-Placebo (cetyl palmitate NPs not containing 
MTX or SPIONs), ii) SLN-MTX (cetyl palmitate NPs containing only MTX), iii) SLN-SPIONs (cetyl 
palmitate containing only SPIONs) and iv) SLN-MTX/SPIONs (cetyl palmitate containing both MTX and 
SPIONs). 
 
4.2.1.3. Antibody conjugation to the Solid Lipid Nanoparticles 
As previously stated, the SLN were further functionalized with an anti-CD64 antibody that is able 
to recognize macrophage’s CD64 (present in the macrophage cell membrane and over expressed in 
RA). This recognition is performed by the antibody’s Fc region and because of this any attempt of 
antibody conjugation must be done through the antibody’s Fab fragment in order to maintain its 
functionality [69]. Considering this, the conjugation reaction performed in two steps: i) the NP’s 
carboxylic groups (present in the stearic acid that was integrated into the SLN matrix) were activated 
in the presence of EDC and NHS, and ii) the antibody’s primary amine (Fab fragment) reacted with 
the activated carboxylic group to form a stable amide bound between the SLN surface and the 
antibody [35]. 
230 mg of Cetyl 
Palmitate
30 mg of Stearic Acid
140 mg of Tween 60
Heat up till 70ºC
Dissolve 4 mg of MTX
Add 40 µL of SPIONs
add 4.400 mL of water
High Shear 
Homogenization
for 30 secs at  12000 
rpms
Sonication
for 5 minutes at 80% 
amplitude
Store in glass flasks at 
room temperature
- Characterization
- Functionalization
- Etc
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Figure 4-2 – Schematic representation of the NP functionalization procedure’s several reactions. Adapted 
from [35].  
 
The NP formulations were diluted in 10 mL of MES buffer, pH 5.0 (this value of pH ensures 
maximum EDC attachment to carboxylic groups), so that the final concentration is 10 mg of NPs per 
mL of buffer. The NPs were then activated by adding 1 mL of 0.1 M EDC and 1 mL of 0.7 M NHS (both 
dissolved in MES buffer, pH 5.0) to the previously prepared suspension. The NP suspension was then 
kept at room temperature under moderate stirring for 1h. 1 mL of the activated-NP suspension was 
transferred to an Eppendorf® tube and 10 µL of the anti-CD64 antibody solution were added to the 
latter. The resulting suspensions were then homogenized with a vortex and incubated at 4ºC for 24h. 
The functionalized NPs were then stored at 4ºC until further usage [35]. 
 
4.2.2. Nanoparticle characterization 
4.2.2.1. Dynamic light scattering and phase analysis light 
scattering 
Dynamic light scattering (DLS), also known as photon correlation spectroscopy or quasi-elastic 
light scattering, is a commonly used technique for the determination of size distribution profiles in 
the sub-micron range. The technique is based on the Brownian motion, that is, particles and 
molecules are in constant random motion and the speed at which they move is related to their size 
(smaller particles move faster that larger ones). The movement speed can be determined by 
measuring the changes of the scattered intensity at a specific angle through time and, taking into 
account the temperature of the suspension, the hydrodynamic radius of the NPs can be determined 
was well as its size distribution [70]. 
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Zeta potential is a physical property related to the charge of a particle and can be used to infer 
on the stability of a suspension or system. When the modulus of the zeta potential is high the particles 
tend to repel each other, due to strong electric charges, and hence do not tend to agglomerate. 
However if the modulus is low the electric charges will not have enough force to repel each other 
and the particles will have a tendency to form agglomerates. The zeta potential can be measured by 
phase analysis light scattering (PALS), that relies on applying an electric field to the suspension that 
will force the particles to move the electrodes depending on their charge. The movement speed of 
the particles is dependent of the field applied and of the particles zeta potential, since the field is 
known the zeta potential can be easily determined [71]. 
The NP formulations were characterized in terms of particle diameter, diameter distribuition 
profile (polydispersity index - PdI) and zeta potential by upper mentioned techniques. Mean diameter 
and PdI were determined by DLS using a 90Plus Particle Size Analyzer (Brookhaven Instruments 
Corporation, Holtsville, NY, USA) and the zeta potential was assessed by PALS using a ZetaPALS Zeta 
Potential Analyzer (Brookhaven Instruments Corporation, Holtsville, NY, USA), at 660 nm, at 20ºC 
with a detection angle of 90º. The formulations were previously diluted in water, the non-conjugated 
NPs 400x and the conjugated NPs 4x, to achieve a final concentration of 250 µg of NP per mL for all 
formulations. All measurements were performed with three independent batches of NPs, with six runs 
each. 
 
4.2.2.2. Transmission Electron Microscopy 
Transmission electron microscopy (TEM) uses an electron beam to illuminate ultra-thin samples 
(under 0.5 µm thick). The electrons interact with the sample and those that pass through it are 
collected by a system of electromagnetic lenses that greatly magnifies and focus the image. The 
image formed is collected and displayed in an imaging device, such as a florescent screen, on a layer 
of photographic film or, more commonly, its detected by a sensor such as a CDD camera. 
Prior to the TEM analysis, the non-conjugated NP suspensions were diluted 100X in water to 
achieve a 1 mg/mL concentration, since the conjugated NPs were already at this concentration (result 
of the functionalization procedure). Samples were prepared by placing 10 µL of NP dispersion on a 
copper-mesh grid (one grid for each different sample) and after 2 minutes the excess of suspension 
was removed with filter paper. As a contrasting agent, 10 µL of 0.75% uranyl acetate solution were 
placed on the grid and after 30 seconds the excess was removed using filter paper. The grids were 
after observed in a JEM-1400 Transmission Electron Microscope (JEOL Ltd.), with an accelerating 
voltage of 80 kV. 
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4.2.2.3. MTX Quantification 
Spectrophotometry is a technique that allows for a quantitative measurement of the amount of 
radiation that a samples absorbs. A beam of light (visible or not) passes through a sample and the 
amount of light that reach the detector is measured. The amount of light that a molecule absorbs, 
at a specific wavelength, can then be used to determine the amount of that molecule that is present 
in the solution. UV/Vis spectrophotometry was used to determine the amount of MTX present in the 
formulations using an indirect method, i.e. the amount of drug that was present outside the NPs was 
dosed, and the association efficiency was determined by subtracting the amount of MTX that 
remained in the aqueous phase to total amount of MTX (equation 1). 
(1) Association efficiency (%) =  
Total amount of MTX−Amount of MTX in the supernatant
Total amount of MTX
× 100 
 
Firstly the NP suspensions were diluted 200x and filtrated with Amicon ® Ultra Centrifugal Filters 
Ultracell-50 kDa (EMD Millipore, Darmstadt, Germany) at 3500 G for 30 minutes using a HeraeusTM 
MultifugeTM X1R centrifuge (Thermo Scientific, Waltham, MA, USA). The resulting supernatant was 
collected for MTX quantification by spectrophotometry. The absorbance of the supernatant was then 
read using a V-660 UV/Vis Spectrophotometer (Jasco Inc., Easton, MD, USA), and the values of the 
absorbance were registered at 299 nm wavelength (MTX absorbance peak). The readings of each 
sample, containing MTX, were corrected using the supernatant resulting from filtration of the 
respective formulation without MTX (SLN-placebo was used as baseline for SLN-MTX, and SLN-SPIONs 
was used as baseline for SLN-MTX/SPIONs) in order to minimize formulation interferences. Each 
sample reading was performed in triplicate (each from an independent batch of NP formulations). 
A calibration curve was constructed using standard solutions of MTX with the final concentrations 
of 0.000625, 0.00125, 0.0025, 0.005, 0.010, 0.020, 0.030 and 0.040 mg/mL. In order to minimize 
reading interferences these standard solutions were prepared in the supernatant resulting from the 
previously described filtration of SLN-placebo NP suspension.  
 
Figure 4-3 – Standard curve for MTX quantification using spectrophotometry. 
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4.2.2.4. Fourier Transform Infrared spectroscopy 
Fourier transform infrared (FT-IR) spectroscopy is a technique that allows the identification of 
samples specific molecular bonds that can used to identify components. It uses an infrared beam that 
passes through the sample and collects an absorbance/transmittance spectrum whose peaks 
correspond to the frequencies of vibrations between the bonds of the chemical elements present in 
the sample. Because each different material is a unique combination of atoms, the infrared spectrum 
works as molecule fingerprint making it possible to identify, with great certainty, the components of 
the sample[72]. FT-IR analysis proved extremely useful in determining the presence of both MTX and 
antibody within the NP formulations. 
Prior to FT-IR analysis the NP formulations were lyophilized, firstly 1 mL of NP suspension was 
frozen at -80ºC for 30 minutes and after place in a Bench Top Pro with Omnitronics (SP Scientific, 
Warminster, PA, USA) at -80ºC at 150 mTorr for 18h. The resulting powders were then characterized 
by FT-IR analysis, using a Frontier FT-IR Spectrometer with Universal ATR Sampling Accessory 
(PerkinElmer, Waltham, MA, USA). Each of the infrared spectrum was collect with 32-scans with 4 
cm-1 resolution in the mid-infrared region (3700 to 600 cm-1). 
 
4.2.2.5. Antibody Quantification 
The amount of antibody conjugated to the NPs was indirectly determined by quantifying the total 
amount of protein of the formulation that was not linked to the NPs. In order to separate the free 
antibody from the NP-conjugated antibody the conjugated NP suspension was centrifuged at 33000 G 
for 5h, and the supernatant was carefully collected. 
The antibody was after quantified using a colorimetric method with the Thermo ScientificTM 
Coomassie (Bradford) Protein Assay Kit. This kit allows for a quick and viable quantification of the 
total amount of protein present – when Coomassie dye binds to a protein, in acidic medium, it 
produces an immediate color change from brown to blue, resulting in a shift of the maximum 
absorbance peak from 465 nm to 595 nm [73]. 
Firstly a calibration curve for the amount of protein was constructed (Figure 4-3) using standard 
bovine serum albumin (BSA) solutions with concentrations of 25, 20, 15, 10, 5, 2.5 and 0 µg/mL of 
BSA in PBS. In order to measure the absorbance of both standard solutions and samples, the micro 
microplate protocol was used. 150 µL of the standard solutions/samples were transferred to a 96-
well plate, in triplicate, and 150 µL of the coomassie reagent was added to those plates. The 96-well 
plate was stirred for 30 seconds and left to incubate at room temperature protected from the light. 
The plate was then read at 595 nm using a SynergyTM HT Multi-mode Microplate Reader (Biotek 
Instruments Inc., Winooski, VT, USA). 
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Figure 4-4 – Standard curve for total protein quantification using spectrophotometry. 
 
The total amount of protein present in the supernatant (free antibody) was then calculated using 
the previously constructed calibration curve, and the conjugation efficiency was determined using 
Equation 2. 
(2) Conjugation efficiency (%) =  
Total amount of antibody−Amount of free antibody
Total amount of antibody
× 100 
 
4.2.3. In Vitro Studies 
THP-1 (ATCC® TIB-202TM), cultured in DMEM medium supplemented with 10% FBS and 1% 
Penicillin-Streptomycin, incubated in a humidified environment at 37ºC with 5% CO2 enriched 
atmosphere. To perform subculture the cells were collected and centrifuged at 300 G and re-
suspended in fresh medium and counted using a Neubauer chamber, diluted in a Trypan Blue solution 
0.4% (w/v) in PBS in order to distinguish viable cells from the non-viable ones. The cells were then 
transferred to a new culture flask to achieve o final cellular concentration of 2*105 cells/mL and the 
total amount of medium was adjusted to the flask size [74]. 
 
4.2.3.1. MTT Assay 
The MTT assay is a colorimetric assay that enables the assessment of cellular metabolism and 
inference on cellular viability. It measures the activity of cellular enzymes that are capable of 
reducing the thiazol blue tetrazolium bromide (MTT) substrate to form insoluble formazan crystals, 
which present a purple color instead of blue [75]. Prior to the assay a calibration curve was 
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constructed to determine the optimal cellular seeding density to be used in the assay, i.e., ensure 
that the measurements fall within the linear detection range. To construct the curve 200 µL of cellular 
suspensions at 1000, 10000, 20000, 40000, 60000, 80000, 100000, 120000, 150000 and 200000 
cells/mL were seeded into a 96-well tissue culture test plates (Orange Scientific Products, Belgium), 
in triplicate. The cellular suspensions were in DMEM culture medium supplemented with 10% FBS and 
1% Penicillin-Streptomycin, with 0.02 µL/mL of PMA (a differentiation agent that causes the THP-1 
cells to adhere to plate). The 96-well plates were incubated at 37ºC with 5% CO2 enriched atmosphere 
for 24h. The medium was then removed and replaced with 200 µL of fresh warm DMEM culture medium 
supplemented with 10% FBS and 1% Penicillin-Streptomycin and incubated at 37ºC with 5% CO2 
enriched atmosphere for another 24h. After 24h of incubation the medium was removed, 5 mg/mL 
MTT dye solution in PBS were diluted in culture medium to achieve a final concentration of 0.5 mg/mL 
and 200 µL of the latter solution were added to each well. The 96-well plate was incubated at 37ºC 
with 5% CO2 enriched atmosphere, protected from the light for 4h. After 4h the plate was removed 
from the incubator, the MTT solution was removed and 200 µL of DMSO were added, to dissolve the 
formazan crystals. The absorbance was then read by using a SynergyTM HT Multi-mode Microplate 
Reader (Biotek Instruments, USA) at 590 nm and 630 nm, the latter was used for background 
subtraction. The obtained results were used to construct a calibration curve (Figure 4-4), and the 
cellular density of 60x103 cells/mL was chosen as the optimal density since was registered 
approximately in the middle of linear portion of the curve. 
 
Figure 4-5 – Standard calibration curve for cell seeding density on the MTX assay. Mean Values ± Standard 
deviation values shown, with n=3. 
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and 1% Penicillin-Streptomycin, with 0.02 µL/mL of PMA) were seeded into a 96-well tissue culture 
test plates (Orange Scientific Products, Braine-l’Alleud, Belgium), in quintuplicate. The 96-well plates 
were incubated at 37ºC with 5% CO2 enriched atmosphere for 24h, after this the medium was removed 
and replaced with 200 µL of fresh warm DMEM culture medium (supplemented with 10% FBS and 1% 
Penicillin-Streptomycin) and incubated at 37ºC with 5% CO2 enriched atmosphere for another 24h. 
After 24h of incubation the medium was removed and 200 µL (100 µL of medium + 100 µL of PBS) of 
NP suspension were added with the final concentrations of (0.05, 0.5, 5, 50 and 500 µg/mL). A positive 
control (100 µL of medium + 100 µL of PBS) and negative control (200 µL of TritonTM X-100 2% (w/v) 
in PBS) as well as a control of free MTX (at the same relative concentrations as the NP suspensions) 
were also include to normalize and better compare results. After 24h of incubation at 37ºC with 5% 
CO2 enriched atmosphere, the MTX assay was performed as previously described. Cellular viability 
was then determined using equation 3. 
(3) Viability (%) =  
Experimental Value−Negative Control
Positive Control− Negative Control
× 100 
 
4.2.3.2. LDH Assay 
Lactate dehydrogenase (LDH) is a cytosolic enzyme present in a wide variety of cellular types that 
catalyzes the metabolism of lactate. This enzyme is released into the culture medium if the cellular 
membrane is damaged and can, therefore, be used to assess cytotoxicity levels and cellular death by 
membrane lysis. It can be easily quantified by using the LDH Cytotoxicity Detection kit that works by 
quantifying the amount of red formazan product formed in the cellular supernatant after incubation 
with the kit’s reaction mixture. The level of formazan formed is directly proportional to the amount 
of LDH released into the medium and, therefore, its activity can be determined [76].  
The LDH assay was done in parallel with the MTT assay, since they share several steps, namely 
the 96-well plate seeding and differentiation and the 24h of incubation at 37ºC with 5% CO2 enriched 
atmosphere, either with the medium and with NP dispersions at various concentrations. After the 
incubation with the free MTX or NP dispersions, the medium was removed and transferred to another 
96-well plate to perform the LDH assay. The resulting 96-well plates were centrifuged for 10 minutes 
at 250 g at room temperature. Carefully, not to disturb the resulting pellet, 100 µL of the supernatant 
from each well were transferred to another 96-well plate. 100 µL of LDH reaction mixture were then 
added to each well and the plates were incubated at room temperature, protected from light for 20 
minutes. After incubation the absorbance was then read using a SynergyTM HT Multi-mode Microplate 
Reader (Biotek Instruments, Highland Park, Winooski, USA) at 490 nm and 630 nm, the latter was used 
for background subtraction. The NP cytotoxicity was determined using Equation (4). It is important 
to note that since a cytotoxicity assay was performed, the negative control used were the cells culture 
with medium+PBS and the positive control were the cells cultured with TritonTM. 
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(4) Cytotoxicity (%) =  
Experimental Value−Negative Control
Positive Control− Negative Control
× 100 
 
4.2.4. Statistical analysis 
Statistical analyses were performed using IBM® SPSS® Statistics (SPSS 22.0, USA). Results are 
presented as mean value ± standard deviation from a minimum of three independent experiments. 
Two-tailed student’s t-test and one-way analysis of variance (ANOVA) were performed to compare 
multiple groups of independent samples, respectively. When the groups showed significant statistical 
difference (p≤0.05), the differences between the respective groups were compared with a post-hoc 
test (Tukey, p≤0.05). Paired (non-independent) samples were analyzed with a paired-samples two-
tailed student’s t-test. Differences were once again considered significant at p≤0.05. 
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5. Results and discussion 
 
As previously stated four different formulations were prepared: i) cetyl palmitate SLNs, ii) MTX-
loaded cetyl palmitate SLNs, iii) SPIONs-loaded cetyl palmitate SLNs and iv) MTX- and SPIONs-loaded 
cetyl palmitate SLNs. For the formulations to the effective in the treatment and diagnostics of AR it 
is of the up most importance to ensure that both the therapeutic and the imaging agents, MTX and 
SPIONs respectively, are properly integrated into the NPs [22, 25, 39, 42]. 
Indications that this integration occurred were seen immediately after NP production without any 
kind of complex characterization. The NP formulations presented distinct color depending if they 
were placebo SLN or encapsulated with one or both of agents, as shown in Figure 5-1. The difference 
between the colors of the formulations was the first indication that the encapsulation of both MTX 
and SPIONs, separately and simultaneously, occurred during the production phase. 
 
Figure 5-1 – Multifunctional NP formulations prepared by an organic solvent-free emulsification-sonication 
method that combined high shear homogenization and ultra-sonication. (A) cetyl palmitate SLNs, (B) MTX-
loaded cetyl palmitate SLNs, (C) SPIONs-loaded cetyl palmitate SLNs and (D) MTX- and SPIONs-loaded cetyl 
palmitate SLNs. 
 
5.1. Nanoparticle characterization 
The properties and characteristics of the NPs influence the formulation stability and can also 
influence their future interactions with cells and tissues, so they were extensively characterized in 
terms of NP size, PdI, Zeta potential, MTX and SPIONs encapsulation as well as antibody-conjugation. 
These characteristics are summarized in Table 2-1 for all NP formulations. 
A B C D 
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Table 5-1 – Physicochemical properties of the NP formulations. Size, PdI and Zeta potential for all the 
formulations and MTX association for the MTX-loaded and MTX- and SPIONs-loaded SLN prior to NP 
functionalization and post-functionalization. 
Formulation Size (nm) PdI Zeta Potential (mV) MTX Association (%) 
SLN 161.00 ± 2.73 a 0.190 ± 0.008 a -39.58 ± 0.87 a - - - 
SLN +  MTX 173.97 ± 3.40 a 0.195 ± 0.013 a -35.06 ± 1.09 a 98.23 ± 8.82 
SLN + SPIONs 243.97 + 4.00 a 0.254 ± 0.008 -28-65 ± 0.74 a - - - 
SLN + MTS + SPIONs 227.60 ± 3.67 a 0.256 ± 0.006 -24.73 ± 0.55 a 105.68 ± 4.75 
SLN + Anti-CD64 113.67 ± 2.93 c 0.081 ± 0.019 c -22.95 ± 0.80 c - - - 
SLN + MTX + Anti-CD64   98.47 ± 5.33 c 0.135 ± 0.028 c -21.93 ± 0.85 c 98.23 ± 8.82 
SLN + SPIONs + Anti-CD64 147.17 ± 8.57 b,c 0.173 ± 0.030 b,c -12.86 ± 0.76 b,c - - - 
SLN + MTX + SPIONs + Anti-CD64 161.13 ± 3.13 b,c 0.171 ± 0.023 b,c -14.01 ± 0.80 b,c 105.68 ± 4.75 
Values shown in mean ± standard deviation (n≥3) 
a – Significantly different (p≤0.05), between non-conjugated formulations. 
b – Significantly different (p≤0.05), between conjugated formulations. 
c – Significantly different (p≤0.05), between after and before functionalization. 
 
5.1.1. Nanoparticle size, Polydispersion Index and Zeta 
Potential 
It has been widely documented that NPs for intravenous applications should present sizes in the 
range of 100 to 300 nanometers [18, 77, 78]. It has also been verified that particles around 250 nm 
are more easily incorporated into macrophages [30, 79], which are the primary target cells of this 
proposed approach. All of the NP formulations presented diameters that were comprised from 100 to 
250 nm (Table 2-1), making them suitable for the intended administration route. 
Regarding the non-conjugated formulations a significant increase in size can be observed when 
SPIONs are encapsulated into the SLNs whereas the encapsulation of MTX does seem to influence 
significantly the size of the NPs. These results suggest that the SPIONs could be altering the structure 
and/or organization of the lipids in the SLN matrix. Conjugated formulations presented unexpected 
results, the association of anti-CD64 should increase the NP diameter yet the results showed that the 
opposite occurred (Table 2-1). Upon a more thorough analysis if the DLS results it was observed that 
the smaller populations of NPs were more numerous (larger particles diffract more intensity of light 
[70]). During the functionalization procedure the NP formulations were diluted approximately 400x, 
during this dilution only the smaller NPs could have been collected leading to a decrease in the 
particle’s overall dimensions that might justify the unexpected results. Considering the size 
distribution profile, the PdI values, for all of the formulations considered, were below the reference 
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value of 0.3, which is indicative of mono-dispersed NP populations presenting uniform NP diameters 
with little agglomeration [70]. 
Concerning the zeta potential results, all the prepared formulations presented distinct negative 
values (Table 2-1). The surface charge of SLNs depend on the lipids and the surfactant used, particular 
cetyl palmimate and Tween 60 SLNs present a negative surface charge that decreases (value in 
modulus increases) with the percentage of Tween 60 used due to its oxygen-rich head groups. 
Additionally, stearic acid was also incorporated into the SLN and lead to a decrease in zeta potential 
values (results obtained during the NP optimization phase) due to the increase of carboxylic groups 
on the SLN surface, potentially increasing the formulation stability. It has been described that 
negatively charged particles have reduced cellular uptake, due to electrostatic repulsion between 
them and the cellular membrane, but also show less cytotoxicity that cationic NPs that can have been 
proven to be able to disrupt the cellular membrane and consequently cell death [41, 43, 59]. 
A slight increase (value in modulus decrease) in zeta potential values was seen with the 
encapsulation of SPIONs into the SLN (Table 2-1). This was not expected since the SPIONs were coated 
with oleic acid (hydrophobic) and should, for this reason, be located in the core of the NP, having no 
significant influence in the surface properties. However, the increase of zeta potential after NP 
functionalization was expected. The antibody conjugation process, previously described, was based 
on a reaction between the antibody’s primary amine and the carboxylic group on the surface charge. 
This causes to potential reasons for zeta potential reaction: i) the antibody itself presents an overall 
positive charge that particle’s charge to increase even if just slightly [80], and ii) the conjugation 
reaction causes a shielding around the carboxylic groups that are used to bind the antibody resulting 
in an increase of the zeta potential.  
Although some results are quite as expected they still suggest the proposed formulations are 
viable and promising candidates for theranostic applications. 
 
5.1.1.1. Nanoparticle formulations stability 
In order to assess the stability of developed formulations, NP size, PdI and zeta potential were 
measured for all of the formulations over the period of one month with three time points (one day, 
seven days and twenty eight days after NP production), results shown in figure 5-2. It can be seen 
that over the period of twenty eight days the formulations remain their properties regarding size, PdI 
and zeta potential allowing to conclude that the developed formulations are stable for at least one 
month. 
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Figure 5-2 – NP properties stability results showing NP diameter (A), PdI (B) and Zeta potential (C). Results shown as mean ± standard 
deviation (n = 3). 
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5.1.2. Transmission electron microscopy 
TEM photographs (Figure 5-2 and Figure 5-3) were taken to corroborate NP size and poly dispersion 
as well as access NP morphology and SPION encapsulation. TEM allowed to confirm the sizes and size 
polydispersions that were previously measured using DLS when considering the placebo and MTX-
loaded SLNs (Figure 5-2 A1, A2, B1, B2) and also showed that the encapsulation of MTX didn’t 
influence the NPs shape. The functionalization of the SLNs also didn’t seem to alter the shape of the 
SLNs that maintained their round spherical-shape (Figure 5-2 E1, E2, F1, F2). The same could not be 
said for the formulations that were encapsulated with SPIONs (Figure 5-2 D1, D2 and Figure 5-3 G1, 
G2, H1, H2). These formulations showed disfigured NPs that in some case formed agglomerations with 
undefined morphology. 
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Figure 5-3 – Transmission electron photographs of (A1, A2) cetyl palmitate NPs, (B1, B2) MTX-loaded cetyl 
palmitate NPs, (C1, C2) SPIONs-loaded cetyl palmitate and (D1, D2) MTX- and SPIONs-loaded cetyl palmitate. 
(A1, B1, C1, D1) total magnification of 15000x with a scale bar corresponding to 1 µm. (A2, B2, C2, D2) total 
magnification of 40000x with a scale bar corresponding to 0.2 µm. 
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Figure 5-4 – Transmission electron photographs of (E1, E2) anti-CD64 conjugated cetyl palmitate NPs, (F1, 
F2) anti-CD64 conjugated MTX-loaded cetyl palmitate NPs, (G1, G2) anti-CD64 conjugated SPIONs-loaded 
cetyl palmitate and (H1, H2) anti-CD64 conjugated MTX- and SPIONs-loaded cetyl palmitate. (E1, F1, G1, 
H1) total magnification of 15000x with a scale bar corresponding to 1 µm. (E2, F2, G2, H2) total 
magnification of 40000x with a scale bar corresponding to 0.2 µm. 
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The photographs taken by TEM (Figure 5-2 D1, D2 and Figure 5-3 G1, G2, H1, H2) were able to 
verify the encapsulation of the SPIONs inside the SLN matrix, although they were found in the 
periphery of the matrix instead of in the core and present in fewer number than expected [35]. These 
unexpected results allow for some conclusions to be taken: i) the agglomerations observed help to 
explain the increase in size detected in the DLS results and ii) the fact that SPIONs are located in the 
inner periphery of lipid matrix could explain the increase in zeta potential when SPIONs were 
encapsulated into SLNs. The SPIONs are coated with oleic acid, making them hydrophobic, and their 
presence in the periphery of the SLN could cause for a re-organization of lipids on the interface 
between the lipid and the surfactant leading an increase in zeta potential. This increase en zeta could 
be sufficient to reduce the formulation overall stability (as explained previously in the correlation 
between zeta potential and formulation stability) and cause the agglomerations observed in the TEM 
photographs. 
 
5.1.3. MTX association efficiency 
The FT-IR spectrum of MTX-loaded SLNs and placebo SLNs were compared with the spectrum for 
MTX alone (Figure 5-4). On the MTX spectrum at 1638 cm-1 a peak can be observed, this peak 
corresponds to a carbon-carbon double bond [81]. This bond is characteristic of the drug and is not 
present on any other compound present on the formulations. This peak, yet faintly, can be seen in 
the MTX-loaded SLNs but not in the SLNs proving the presence of MTX in the formulation. 
 
Figure 5-5 – FT-IR spectrum for MTX-loaded SLNs, placebo SLNs and free MTX. 
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Since the FT-IR is only a qualitative method the encapsulation of MTX was determined by UV/Vis 
Spectrophotometry. The MTX encapsulation was of 95% and of 105%, for MTX-loaded SLNs and for 
MTX- and SPIONs-loaded SLNS respectively. Both encapsulation values are similar and close to 100% 
encapsulation, indicating that the co-encapsulation of MTX and SPIONs is possible and may show 
promise for future theranostic applications. 
 
5.1.4. Antibody conjugation 
The FT-IR spectrum of anti-CD64-conjugated SLNs and placebo SLNs were compared with the 
spectrum for Anti-CD64 alone (Figure 5-5). On the anti-CD64 spectrum at 1560 cm-1 a peak can be 
observed, this peak corresponds to a nitrogen-hydrogen bond [82]. This bond is characteristic of the 
drug and is not present on any other compound present on the formulations, since there is no 
nitrogen. By analyzing the spectrum of the anti-CD64 SLNs it is possible to observe a peak at around 
1560 cm-1 indicating the presence of a nitrogen-hydrogen bond that, as expected, is not present in 
the non-conjugated SLNs denoting the presence of the antibody in the SLNs. 
 
Figure 5-6 FT-IR spectrum for Anti-CD64 conjugated SLNs, non-conjugated SLNs and free anti-CD64. 
 
3700 3200 2700 2200 1700 1200 700
Wavelength (cm-1)
1560 cm-1 
Anti-CD64 SLN 
SLN 
Free Anti-CD64 
42 
 
The quantification of anti-body conjugated was to be performed as previously described, but due 
to incidents regarding the experimental process has not yet possible to quantify. 
 
5.2. In vitro Assays 
5.2.1. Cellular viability and cytotoxicity 
In order to assess the effects of the developed NP formulations on cellular viability and overall 
cytotoxicity, MTT and LDH assays were performed, respectively, on THP-1 cells (differentiated by 24h 
of incubation with PMA). On both tests, the values obtained for the cells incubated with the NPs 
controls were used: cells incubated only with culture medium and PBS for the MTT assay and cells 
treated with Triton X-100 for the LDH assay, as described in the methods sections. A control of free 
MTX was also included, this control considered the potentially encapsulated MTX, with an association 
efficiency of 100% (1 mg of MTX per 100 mg of formulation) since MTX is highly hydrophobic at the pH 
used [83]. 
Regarding these assays, the expected outcomes were that the placebo-SLN and the SPIONs-loaded 
SLN formulation would present no cytotoxicity since the components they contain have been shown 
to be biocompatible [41, 46, 56, 79] and the surfactant was not at high enough concentrations to be 
toxic [84]. Whereas the formulations that contained MTX (MTX-loaded SLNs and MTX- and SPIONs-
loaded SLNs) should influence cellular viability and present cytotoxicity since MTX disrupts aspects of 
cellular metabolism and therefore decreases the cellular proliferation [9, 85]. 
The results, however, were not as expected. The MTT assay (Figure 5-6) showed little variation 
between the cellular viability of cells incubated with NPs of different formulations (comparing among 
the same concentration). This could be explained considering the reduced amount of MTX added to 
the formulations that simply could have not been enough to achieve toxic levels. On the other hand 
only the cells incubated with the highest concentrations of NPs impaired the cellular viability that 
confirms that the formulations are indeed biocompatible and well accepted by the cells. It is also 
important to note that the cells incubated with the higher concentrations of free-MTX showed greatly 
increased viability that was probably due to interferences cause by the large quantities of MTX 
present in the solution. The LDH assay results (Figure 5-7) corroborated the MTT results regarding the 
effects of the different formulations and concentrations, showing an increased cytotoxicity in the 
higher concentrations but no significant variances with different formulations. It is also important to 
take into account that LDH kit does not measure cytotoxicity directly but in turn measures the amount 
of cells that die due to cellular lysis [76]. The NPs could present cytotoxic behavior and die in a way 
that does not cause the cellular membrane to disrupt and, therefore, not being detected by this 
assay.  
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Figure 5-7 – Effect of the developed NP formulations on differentiated THP-1 cells viability as a function of 
the different NP concentrations (500, 50, 5, 0.5 and 0.05 µg/mL) tested. Values represented as mean ± 
standard deviation (n≥3; * statistical significant differences assessed with p≤0.05).  
 
Figure 5-8 – Cytotoxicity of the developed NP formulations on differentiated THP-1 cells as a function of the 
different NP concentrations (500, 50, 5, 0.5 and 0.05 µg/mL) tested. Values represented as mean ± standard 
deviation (n≥3; * statistical significant differences assessed with p≤0.05). 
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Conclusions 
 
The use of SLN for simultaneous drug delivery and in vivo imaging is an interesting approach for 
safe theranostic applications considering their biocompatibility and biodegradability, especially with 
the new possibilities of multifunctionalization brought by nanomedicine. In this work, an innovative 
attempt to achieve a combined therapy and imaging of RA was proposed, by co-encapsulating MTX 
and SPIONs inside cetyl palmitate and stearic acid SLNs. These SLNs were further functionalized with 
anti-CD64, an antibody that specifically binds to a cell surface receptor that is over expressed in RA 
infected macrophages. 
The proposed NP formulations presented interested and promising results for future theranostics 
of RA, regarding both physicochemical properties of the NPs as well interaction with the cell line 
THP-1 differentiated cells.  
Concerning the NP characterization, all the formulations presented dimensions comprised 
between the ranges of 100 nm to 250 nm with PdI values that indicate a monodispersed size profile, 
making them potential and promising candidates for intravenous administration as proposed. These 
results were confirmed, to some extent, by TEM that showed spherical morphology for most of the 
formulations, while also revealing small deformations of the NPs containing SPIONs that help to 
explain some of the results obtained for these formulations in terms of size and zeta potential. 
The zeta potential values for all the formulations were comprise between -12 and -40 mV, as a 
result of the incorporation of stearic acid that integrated the surface of the SLNs leaving it’s 
carboxylic group outwards and exposed. This addition to the formulation not only increased the 
functional groups available for future functionalization purposes but also helped to stabilize the 
formulations. The addition of MTX did not alter the zeta values very significantly, whereas the 
addition of SPIONs caused the values to increase slightly. This was explained by the previously 
mentioned TEM results, which showed a preferential accumulation of SPIONs in the periphery of the 
NPs. The SPIONs were coated with oleic acid that probably caused a re-organization of the lipids in 
periphery that could explain the difference in the zeta potential. 
It was also proven that all of the NP formulations are stable up to one month, with little 
alterations in NP size, PdI and zeta potential over this period of time. 
The encapsulation of both MTX and SPIONs into the formulations was suspected immediately after 
NP production due to the alterations observed in the colors of those same formulations. The 
association of MTX to the formulations was verified by FT-IR spectroscopy that indicated specific 
peaks that were characteristic of the MTX but not the other components present. The association of 
MTX was also quantified by UV/Vis spectrophotometry, and efficiencies of 98% and 105% for the MTX-
loaded SLNs and for the MTX- and SPIONs-loaded SLNs. The encapsulation of SPIONs was proven by 
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TEM, as small very electro dense dots rounding 10 nm in diameter were observed within the SLN 
matrix. 
The successful antibody conjugation was hinted in the zeta potential values, which increased 
(decreased in modulus) in all the formulations after antibody conjugation. This hypothesis was 
verified using FT-IR spectroscopy that enable the verification of peak specific to the antibody and not 
present in the SLN components. 
Finally the in vitro assays showed that the NPs presented low toxicity after 24h of incubation to 
THP-1 cell line, with exception for the highest concentrations. Proving that the proposed formulations 
were indeed safe for future theranostic applications. 
In conclusion, the results proved that the proposed formulations are very promising for the future 
of RA treatment and diagnostic/monitoring, by providing a safe and targeted delivery of therapeutic 
agents and simultaneously allowing in vivo imaging. There is, however, still much to be done and 
more comprehensive and detailed studies should be performed in order for approaches such as this 
one to leave the lab and move to the clinic, but the pavement is being laid for such a time. 
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Future work 
 
In order to further characterize the NP formulations, the efficiency of antibody-conjugation 
should be assessed as well as the effects of antibody-conjugated NP on the viability and cytotoxicity 
in in vitro assays. Studies to optimize the amount of MTX and SPIONs encapsulation in the formulations 
should also be performed in order to maximize the therapeutic effect and imaging capability. Similar 
studies should also be performed to optimize the antibody ratio. Studies to determine the 
crystallization degree of encapsulated-MTX would also be recommended, since this degree will 
influence drug release.  
Considering SLN production method, a purification procedure should also be added in order to 
allow the removal of production/conjugation excesses. A potential procedure would be ultra-
centrifugation of the formulations, such a process would also have to be optimize to ensure proper 
separation between the NPs and the suspension medium. 
Regarding the NP characterization, studies using SPIONs non-coated with oleic acid could be 
performed, in order to assess if they could be encapsulated with altering the stability of the SLNs (as 
explained in the TEM results). 
Concerning the in vitro assays, cellular uptake assays should be performed to determine whether 
or not the NPs are actually penetrating the cellular membrane and what is the internalization 
mechanism responsible for this. 
Looking a bit further down the road, perhaps a secondary functionalization with PEG-chains in 
order to make the particle less recognizable to the immune system increasing its potential 
effectiveness as a theranostic agent. Such a coating could also alter the antibody conjugation tested 
in the assay, by linking the antibody to the end of the PEG-chain with all the added benefits. 
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